Highly potent and selective chiral inhibitors of PDE5: An illustration of Pfeiffer's rule

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 23, 2008, Pages 6033-6036

  Bunnage, Mark E ^a   Mathias, John P ^a   Wood, Anthony ^a   Miller, Duncan ^a   Street, Stephen D A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Eudismic; Eudismic analysis; Non linear pharmacokinetics; PDE5; PDE5 inhibitor; Pfeiffer's rule; Sildenafil; UK 343,664; UK 371,800

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; UK 343664; UK 371800; UNCLASSIFIED DRUG;

ARTICLE; CHIRALITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASES; COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 6; DOSE-RESPONSE RELATIONSHIP, DRUG; ERECTILE DYSFUNCTION; HUMANS; MALE; MOLECULAR STRUCTURE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 55549140788     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.10.037     Document Type: Article

References (21)

1. Terrett N.K., Bell A.S., Brown D., and Ellis P. Bioorg. Med. Chem. Lett. 6 (1996) 1819
2. Maw G.N. Annu. Rep. Med. Chem 34 (1999) 71
3. Eardley I. Exp. Opin. Invest. Drugs 6 (1997) 1803
4. Rotella D.P. Nature Rev. Drug Discov. 1 (2002) 674
5. Pissarnitski D. Med. Res. Rev. 26 (2006) 369
6. Abel S., Beaumont K.C., Crespi C.L., Eve M.D., Fox L., Hyland R., Jones B.C., Muirhead G.J., Smith D.A., Venn R.F., and Walker D.K. Xenobiotica 31 (2001) 665
7. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Del. Rev. 23 (1997) 3
8. For a recent analysis of the association between rule-of-5 violation and development attrition, see: Leeson, P. D.; Springthorpe, B. Nature Rev. Drug Discov. 2007, 6, 881.
9. For an analysis of ligand complexity and probability of binding, see: Hann, M. M.; Leach, A. R.; Harper, G. J. Chem. Inf. Comput. Sci. 2001, 41, 856.
10. Bunnage, M. E.; Mathias, J. P.; Street, S. D. A.; Wood, A. PCT Int. Appl., 1999, WO 9954333.
11. (R)-(-)-1-methoxy-2-propanol is commercially available from a variety of suppliers, including Fluka & Acros.
12. D +16.6° (c 0.10, methanol).
13. 2 = 0.98).
14. See Ref. 10 for description of PDE5 and PDE6 assays. A detailed protocol from our laboratories for PDE5 and PDE6 assays can also be found in: Allerton, C. M. N.; Barber, C. G.; Beaumont, K. C.; Brown, D. G.; Cole, S. M.; Ellis, D.; Lane, C. A. L.; Maw, G. N.; Mount, N. M.; Rawson, D. J.; Robinson, C. M.; Street, S. D. A.; Summerhill, N. W. J. Med. Chem. 2006, 49, 3581.
15. Pfeiffer C.C. Science 124 (1956) 29
16. Van de Waterbeemd H., Tayar N.E., Testa B., Wikström H., and Largent B. J. Med. Chem. 30 (1987) 2175
17. Lehmann P.A., Rodrigues de Miranda J.F., and Ariëns E.J. Prog. Drug. Res. 20 (1978) 101
18. Crystallographic studies of compound 8 (UK-371,800) in PDE5 have recently been disclosed that indicate a 'flipped' binding mode compared to sildenafil. Homology analysis of this structure with PDE6 provides a structure-based rationale for the enhanced selectivity seen this series, see: Palmer, M. J.; Bell, A. S.; Fox, D. N. A.; Brown, D. G. Curr. Top. Med. Chem. 2007, 7, 405.
19. Crossley R. Tetrahedron. 38 (1992) 8155
20. Reported Log Ds are measured values.
21. 6